Association of serum iron studies in COVID associated mucormycosis with stage of the disease
DOI:
https://doi.org/10.18203/2320-6012.ijrms20231615Keywords:
Mucormycosis, SARS-CoV-2, Serum iron profileAbstract
Background: Mucormycosis is a rare and lethal invasive fungal infection caused by opportunist and ubiquitous fungi. India has reported surge in cases of post COVID 19 mucormycosis due to the increasing frequency of risk factors like corticosteroid therapy, uncontrolled diabetes, DKA, neutropenia and iron overload and hence warrants a detailed study to identify potential contributing factors. Aim of this study was to study the clinical profile of patients with CAM and to correlate serum iron studies with severity and extent of disease in CAM patients.
Methods: This prospective crosssectional study was conducted on 75 patients with CAM admitted to Bowring Hospital, Bangalore. Detailed history with clinical evaluation and appropriate investigations done and data was analysed.
Results: The mean age of the subjects was 48.19 with 52 males and 23 females. Among 75 patients 90.7% were unvaccinated against COVID, 62.7% had oxygen and steroid use, with diabetes mellitus as most common comorbidity. Rhino orbital-cerebral mucormycosis was the most common clinical presentation. Patients with stage 4 CAM had elevated levels of inflammatory markers LDH (292), D-dimer (457), CRP (74.64), mean serum iron (50.37) and TIBC (255.37). Case fatality rate was 12%.
Conclusions: The results of this study revealed significant correlation between the clinical severity of CAM and higher mortality, with increased serum iron levels and inflammatory markers. Therefore patients with elevated levels of available serum iron are uniquely susceptible to mucormycosis infection, suggesting dysregulated iron metabolism in its pathogenesis.
Metrics
References
Ibrahim AS, Edwards JE, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58(5):1070–3.
Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis:the disease spectrum in 27 patients. Mycoses. 2007;50:290e296.
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266-75,
Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020;285:198005.
Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020;185(4):599-606.
Suganya R, Malathi N, Karthikeyan V, Janagaraj VD. Mucormycosis: a brief review. J Pure Appl Microbiol. 2019;13(1):161-5.
López-Martínez R. Ecology of fungi pathogenic to man. Scientia Fungorum. 2005;(21):85-92.
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-9.
Aranjani JM, Manuel A, Abdul Razack HI, Mathew ST. COVID-19 associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS neglected tropical diseases. 2021;15(11):e0009921.
Goddanti N, Reddy YM, Kumar MK, Rajesh M, Reddy LS. Role of COVID 19 inflammatory markers in rhino-orbito-cerebral mucormycosis: a case study in predisposed patients at a designated nodal centre. Indian J Otolaryngol Head Neck Surg. 2021:1-7.
Tabassum T, Araf Y, Moin AT, Rahaman TI, Hosen MJ. COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression. Mol Biol Rep. 2022;49(1):747-754.
Bhadania S, Bhalodiya N, Sethi Y, Kaka N, Mishra S, Patel N, et al. Hyperferritinemia and the Extent of Mucormycosis in COVID-19 Patients. Cureus. 2021;13(12):e20569.
Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543-e552.
Downloads
Published
How to Cite
Issue
Section
